10 completed, 3 terminated, 1 unknown. 14 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 10, Terminated 3, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Hepatitis C Infection: new trials by email Literature Review of Hepatitis C Infection trials Research Report on Hepatitis C Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection Glecaprevir/Pibrentasvir (G/P) - Hepatitis C Infection, HIV Infection | Phase 2 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 45 | 2019-11-20 | 2024-07-11 |
| Pembrolizumab (MK-3475) in Hepatocellular Carcinoma Elbasvir/Grazoprevir, Laboratory Biomarker Analysis, Pembrolizumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 15 | 2016-12-09 | 2025-07-15 |
| Interaction Between Paroxetine and Telaprevir Paroxetine, telaprevir - Hepatitis C Infection, Depression | Phase 2 | Terminated | Radboud University Medical Center | 3 | 2013-05-01 | 2020-12-08 |
| Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C MBL-HCV1, Telaprevir (Part 1), Sofosbuvir (Part 2) - Hepatitis C Infection | Phase 2 | Terminated | MassBiologics | 11 | 2012-11-21 | 2021-02-05 |
| Effects of Vitamin D on Inflammation in Liver Disease Vitamin D, Placebo - Hepatitis C Infection, Vitamin D Deficiency | Phase 2 | Unknown | Veterans Medical Research Foundation | 24 | 2011-11-01 | 2012-12-21 |
| Study of SCY-635, Pegasys and Copegus in Hepatitis C Placebo, SCY-635, Pegasys - Hepatitis C Infection | Phase 2 | Completed | Scynexis, Inc. | 10 | 2010-11-01 | 2017-08-18 |
| A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures Nitazoxanide With Pegylated Interferon And Ribavirin - Hepatitis C Infection, HIV Infection | Phase 1 / Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 8 | 2010-08-01 | 2021-10-05 |
| Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia romiplostim, ribavirin, placebo - Hepatitis C Infection, Thrombocytopenia | Phase 2 | Terminated | University of Southern California | 27 | 2010-06-30 | 2017-04-11 |
| An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject BMS-790052, BMS-650032 - Hepatitis C Infection | Phase 2 | Completed | Bristol-Myers Squibb | 43 | 2010-04-01 | 2015-10-09 |
| Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects Nitazoxanide (NTZ), Pegylated interferon alfa-2a (PEG), Ribavirin (RBV) - HIV Infection, Hepatitis C Infection | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 68 | 2010-01-01 | 2021-11-04 |
| Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin) Daclatasvir, Placebo, Peginterferon alfa-2a - Hepatitis C Infection | Phase 2 | Completed | Bristol-Myers Squibb | 55 | 2009-12-01 | 2015-09-11 |
| Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients BMS-790052, Placebo, Peginterferon alfa-2b - Hepatitis C Infection | Phase 2 | Completed | Bristol-Myers Squibb | 51 | 2009-12-01 | 2015-10-12 |
| Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin) Daclatasvir, Placebo, Peginterferon alpha-2a - Hepatitis C Infection | Phase 2 | Completed | Bristol-Myers Squibb | 74 | 2009-06-01 | 2015-10-23 |
| Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection S-adenosyl-L-methionine disulfate p-toluene-sulfonate, placebo, laboratory biomarker analysis - Adult Primary Liver Cancer, Hepatitis C Infection | Phase 2 | Completed | Chao Family Comprehensive Cancer Center | 110 | 2007-10-01 | 2018-08-10 |
Hepatitis C (14) · HIV Infections (3) · Carcinoma, Hepatocellular (2) · Depression (1) · Thrombocytopenia (1) · Vitamin D Deficiency (1)
Blood-Borne Infections (14) · Communicable Diseases (14) · Digestive System Diseases (14) · Flaviviridae Infections (14) · Hepatitis (14) · Hepatitis, Viral, Human (14) · Infections (14) · Liver Diseases (14) · RNA Virus Infections (14) · Virus Diseases (14) · Genital Diseases (3) · Immune System Diseases (3) · Immunologic Deficiency Syndromes (3) · Lentivirus Infections (3) · Retroviridae Infections (3)
Ribavirin (8) · peginterferon alfa-2a (5) · daclatasvir (4) · nitazoxanide (2) · telaprevir (2) · Chromatography, High Pressure Liquid (1) · Immunoenzyme Techniques (1) · Paroxetine (1) · SCY-635 (1) · Sofosbuvir (1) · Vitamin D (1) · asunaprevir (1) · elbasvir (1) · elbasvir-grazoprevir drug combination (1) · glecaprevir and pibrentasvir (1)
Bristol-Myers Squibb (4) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · Chao Family Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · MassBiologics (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institutes of Health Clinical Center (CC) (1) · Radboud University Medical Center (1) · Scynexis, Inc. (1) · University of Southern California (1) · Veterans Medical Research Foundation (1)
United States (10) · Japan (3) · Puerto Rico (2) · Brazil (1) · France (1) · Netherlands (1)
Ahmed O Kaseb, MD (1) · Andrew J Muir, MD (1) · Arthur Y. Kim, MD (1) · David Burger, PharmD, PhD (1) · David Wyles, MD (1) · Howard Liebman (1) · John Hoefs (1) · Keyur Patel, MD (1) · Mario Chojkier, MD (1) · Marion Peters, MD (1) · Shyamasundaran Kotilil, M.D. (1) · Susanna Naggie, MD, MHS (1)
PMID 22714001, PMID 23178977, PMID 23183526, PMID 24468783, PMID 26130251, PMID 26683763, PMID 40736252
N01CN35160 (1), UM1AI068636 (1)